GLP-1 Tirzepatide ReviewS.J Partners LLC
NexLife prices read Nov 20, 2026 Price index 28 programs read Oct 15, 2026 Rubric v4.1 Corrections open log

Trial review

SURMOUNT-OSA and Tirzepatide for Sleep Apnea

Tirzepatide in obstructive sleep apnoea with obesity

Direct answer

SURMOUNT-OSA was a two phase 3, randomised, double-blind, placebo-controlled trials under one master protocol funded by Eli Lilly and Company. Tirzepatide reduced the apnoea-hypopnoea index, body weight, hypoxic burden, hsCRP and systolic blood pressure, and improved sleep-related patient-reported outcomes. That figure belongs to the population, dose, comparator and 52 weeks shown below, and describes a group average under trial conditions rather than a prediction for any individual.

Answer last reviewed: Evidence:
SURMOUNT-OSA at a glanceVerified
Data table
DesignTwo phase 3, randomised, double-blind, placebo-controlled trials under one master protocol
PopulationAdults with moderate-to-severe obstructive sleep apnoea and obesity. Trial 1 enrolled participants not using positive airway pressure; trial 2 enrolled participants using PAP at baseline
Sample sizenot captured
InterventionTirzepatide once weekly at maximum tolerated dose
ComparatorPlacebo
Duration52 weeks
Primary endpointChange in apnoea-hypopnoea index from baseline
Main resultTirzepatide reduced the apnoea-hypopnoea index, body weight, hypoxic burden, hsCRP and systolic blood pressure, and improved sleep-related patient-reported outcomes
NCT NCT05412004 · DOI 10.1056/NEJMoa2404881 · PMID 38912654Last source check: 2026-07-24
How to read SURMOUNT-OSA without over-reading it
1Who was eligibleAdults with moderate-to-severe obstructive sleep apnoea and obesity. Trial 1 enrolled pa2What they receivedTirzepatide once weekly at maximum tolerated dose3What it was compared againstPlacebo4For how long52 weeks5What was measured firstChange in apnoea-hypopnoea index from baseline6What the group average wasTirzepatide reduced the apnoea-hypopnoea index, body weight, hypoxic burden, hsCRP and s7What it does not tell youA group average is not a prediction for any individual reader.
Show this figure as a table
Data table
StepStageWhat happens
1Who was eligibleAdults with moderate-to-severe obstructive sleep apnoea and obesity. Trial 1 enrolled participants not using positive airway pressure; trial 2 enrolled participants using PAP at baseline
2What they receivedTirzepatide once weekly at maximum tolerated dose
3What it was compared againstPlacebo
4For how long52 weeks
5What was measured firstChange in apnoea-hypopnoea index from baseline
6What the group average wasTirzepatide reduced the apnoea-hypopnoea index, body weight, hypoxic burden, hsCRP and systolic blood pressure, and improved sleep-related patient-reported outcomes
7What it does not tell youA group average is not a prediction for any individual reader.
Strip any step and the result stops meaning what the trial found.
Primary results, from the peer-reviewed publicationNew England Journal of Medicine 2024;391(13)
Intervention groupnot capturedComparator groupnot captured
Show this figure as a table
Data table
ItemWeight changeEvidence
Intervention groupnot captured
Comparator groupnot captured
Bars fill only from the peer-reviewed publication. Topline and press-release figures are labelled as such and are never charted as results.
What this trial can and cannot tell you
What this trial can and cannot tell you
QuestionPosition
Average effect in the studied populationReported once captured
Your individual outcomeNot predicted by any trial
Effect of a compounded preparationNot studied here
Effect at doses outside the protocolNot studied here
Effect after stoppingOnly if the trial included a withdrawal phase
Long-term safety beyond the trialOutside the observation window

Questions readers actually ask

Does this mean I would lose that much weight?

No. Trials report group averages under controlled conditions with specific eligibility criteria. Individual results vary widely, and the trial population may not resemble you.

Do these results apply to compounded tirzepatide?

Not automatically. Trials studied the approved product at studied doses. A compounded preparation at a different concentration, formulation or route has not been through those trials.

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Review. “SURMOUNT-OSA and Tirzepatide for Sleep Apnea.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/research/surmount-osa/

When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Report an error
Comparing 0 of 4